Vivozon Pharmaceutical비보존 제약
082800 · KOSDAQ · ₩082800 · 비보존 제약
- Market cap
- ₩180B
- Enterprise value
- ₩201B
- P/E
- —
- P/B
- 1.9×
- Dividend yield
- 0.0%
- ROE
- −34.4%
- Net margin
- −65.2%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−54.0% from the high
₩2,070Today: ₩2,875 – ₩2,985₩6,430
Returns
- 1W−4.8%
- 1M+6.1%
- 3M+33.3%
- 6M−6.5%
- YTD−23.1%
- 1Y−39.9%
- Volume today
- 73,430
- 0.5× the 20-day average
- Traded today
- ₩215M
- Listed shares
- 60,719,666
- EPS (12 months)
- −₩541
- Earnings yield −18.3%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 34 of 100 (50 is a normal day for this stock).
- MomentumFlat4.6% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Vivozon Pharmaceutical stock overview
Vivozon Pharmaceutical (비보존 제약, KRX: 082800) is listed on KOSDAQ, in the Biotech & Pharma sector. The company is a pharmaceutical firm that manufactures and sells finished prescription and over-the-counter medicines while focusing on research and development of innovative new drugs. Its shares closed at ₩2,960 on Oct 27, 2026, up 2.07% on the day, giving it a market value of ₩180B.
Key facts
- Market cap
- ₩180B
- Sector
- Biotech & Pharma
- Latest price change
- +2.07%
- As of
- Oct 27, 2026
- Main business
- The company is a pharmaceutical firm that manufactures and sells finished prescription and over-the-counter medicines while focusing on research and development of innovative new drugs.
Quick answers about Vivozon Pharmaceutical
- What does Vivozon Pharmaceutical do?
- The company is a pharmaceutical firm that manufactures and sells finished prescription and over-the-counter medicines while focusing on research and development of innovative new drugs. Its main products include cardiovascular, skin, antipyretic-analgesic, and diabetes treatments, along with self-developed OTC brands and an influenza treatment, across roughly 190 items. It conducts ETC (prescription drug), OTC, contract manufacturing (CMO), OEM, and overseas export business, selling mainly in Korea through pharmacies and wholesalers and operating its main production plant in Hwaseong, Gyeonggi Province.
- What is the market cap of Vivozon Pharmaceutical?
- The market capitalisation of Vivozon Pharmaceutical was ₩180B at the close on Oct 27, 2026.
- Who are the largest shareholders of Vivozon Pharmaceutical?
- According to the latest official filings, the largest reported holders are Bevorson Holdings (31.25%, as of Oct 6, 2026); Biovaut (10.36%, as of Aug 7, 2026); Lee Du-hyeon (0.13%, as of Mar 12, 2026).
- When is the next earnings report from Vivozon Pharmaceutical?
- Korean companies rarely announce results dates in advance. Based on when Vivozon Pharmaceutical filed the same report in past years, its next 3q results is expected between Nov 10, 2026 and Nov 14, 2026.
Company profile
The company is a pharmaceutical firm that manufactures and sells finished prescription and over-the-counter medicines while focusing on research and development of innovative new drugs. Its main products include cardiovascular, skin, antipyretic-analgesic, and diabetes treatments, along with self-developed OTC brands and an influenza treatment, across roughly 190 items. It conducts ETC (prescription drug), OTC, contract manufacturing (CMO), OEM, and overseas export business, selling mainly in Korea through pharmacies and wholesalers and operating its main production plant in Hwaseong, Gyeonggi Province.
Written by AI from the company's latest annual report.
- Korean name
- 비보존 제약
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 장부환
- Founded
- Aug 2002
- Listed
- Nov 2005
- Listed shares
- 60,719,666
- Fiscal year ends
- Month 12
- Website
- www.vivozonpharm.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Adjustment of Conversion Price (21st Series)Oct 12, 2026
- 5%+ holding reportOct 6, 2026
- 5%+ holding reportSep 22, 2026
- Insider shareholding reportAug 21, 2026
- Trading Plan Report for Executives and Major Shareholders' Specific SecuritiesAug 19, 2026
Titles in Korean until English translations are added.
Also known as: Vivozon Pharmaceutical / 비보존 제약 / 082800 / KRX:082800
Source: KRX statistical information